<DOC>
	<DOCNO>NCT02609165</DOCNO>
	<brief_summary>This study aim investigate therapeutic potential recombinant human Nerve Growth Factor ( rhNGF ) eye drop treatment patient Retinitis Pigmentosa ( RP ) associate cystoid macular edema ( CME ) phase II , randomize , double-masked , control clinical trial .</brief_summary>
	<brief_title>Nerve Growth Factor Eye Drops Treatment Patients With Retinitis Pigmentosa Cystoid Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>1 . Typical atypical form retinitis pigmentosa ( RP ) 2 . Measurable ERG significant decrease amplitude . 3 . Reduction visual field ( assessed Humphrey field analyzer HFA 242 ) value mean deviation &gt; 3 decibel ( dB ) . 4 . RP associate CME document OCT ( macular thickness great 250 uM ) present least three month treatment least one month ; 5 . Best correct visual acuity ( BCVA ) 20/100 ( 2/10 0.1 logMAR ) 20/25 ( 8/10 0.7 logMAR ) best correct visual acuity near exceed II character 6 . Absence Other ocular confounding diseases 7 . Participant must medically able undergo test study procedure require flowsheet exam procedure . 1 . Presence diabetesrelated macular edema , macular edema associate cause choroideal neovascularization eye surgery . 2. patient diabetes mellitus . 3 . Patients perform eye surgery previous three month . 4 . Evidence active eye infection . 5. previous uveitis evidence intraocular inflammation . 6 . History evidence glaucoma elevate intraocular pressure ( IOP ) great equal 21 mm Hg baseline . 7. abnormality anterior segment medium opacity prevent assessment posterior segment te eye 8 . The treatment corticosteroid ( systemic , periocular intravitreal ) least 3 month . 9 . The use topical medication study drug treatment ocular pathology . 10 . Presence history systemic ocular disease condition may significantly limit visual acuity visual field , hinder effectiveness treatment study evaluation , could interfere interpretation The study result , may judge investigator incompatible visit program procedure study . 11 . Known hypersensitivity study drug drug procedural . 12 . Participation another clinical study period study within 90 day screen visit / baseline . 13 . History drug use , illegal drug alcohol abuse addiction . 14 . Women childbearing potential exclude participation study meet one follow condition : currently pregnant , positive urine pregnancy test screen / baseline , They plan become pregnant treatment period study , They breastfeed , They available use highly effective measure birth control , : oral hormonal contraceptive / mechanical barrier method spermicide conjunction barrier condom diaphragm 'entire course study 30 day treatment period provide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>